This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Catron, D. M.
Right arrow Articles by Haldar, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Catron, D. M.
Right arrow Articles by Haldar, K.

 Previous Article  |  Next Article 

Infection and Immunity, February 2004, p. 1036-1042, Vol. 72, No. 2
0019-9567/04/$08.00+0     DOI: 10.1128/IAI.72.2.1036-1042.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Salmonella enterica Serovar Typhimurium Requires Nonsterol Precursors of the Cholesterol Biosynthetic Pathway for Intracellular Proliferation

Drew M. Catron,1 Yvonne Lange,2 Jayme Borensztajn,3 Matthew D. Sylvester,1 Bradley D. Jones,4 and Kasturi Haldar1*

Departments of Pathology and Microbiology-Immunology,1 Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611,3 Department of Pathology, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612,2 Department of Microbiology, University of Iowa School of Medicine, Iowa City, Iowa 522424

Received 4 August 2003/ Returned for modification 15 October 2003/ Accepted 3 November 2003

We have previously shown that Salmonella enterica serovar Typhimurium infection perturbs the host cholesterol biosynthetic pathway. Here we show that inhibiting the first step of this pathway (3-hydroxy-3-methylglutaryl coenzyme A reductase) reduces the growth of intracellular S. enterica serovar Typhimurium and has no effect on extracellular bacterial growth. Selectively inhibiting synthesis of downstream sterol components has no effect on infection, suggesting that the effect of statins on host nonsterol intermediates is detrimental to bacterial growth. Furthermore, statins also reduce bacterial proliferation in the S. enterica serovar Typhimurium mouse model. This suggests that blocking the production of nonsterol precursors in the host cell can be used to reduce infection.

* Corresponding author. Mailing address: Ward Building, 3rd Floor Room 240, Northwestern University Medical School, 303 East Chicago Avenue, Chicago, IL 60611-3008. Phone: (312) 503-1443. Fax: (312) 503-8240. E-mail: k-haldar{at}northwestern.edu.

Editor: J. T. Barbieri

Infection and Immunity, February 2004, p. 1036-1042, Vol. 72, No. 2
0019-9567/04/$08.00+0     DOI: 10.1128/IAI.72.2.1036-1042.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Tleyjeh, I. M., Kashour, T., Hakim, F. A., Zimmerman, V. A., Erwin, P. J., Sutton, A. J., Ibrahim, T. (2009). Statins for the Prevention and Treatment of Infections: A Systematic Review and Meta-analysis. Arch Intern Med 169: 1658-1667 [Abstract] [Full Text]  
  • Parquet, V., Briolant, S., Torrentino-Madamet, M., Henry, M., Almeras, L., Amalvict, R., Baret, E., Fusai, T., Rogier, C., Pradines, B. (2009). Atorvastatin Is a Promising Partner for Antimalarial Drugs in Treatment of Plasmodium falciparum Malaria. Antimicrob. Agents Chemother. 53: 2248-2252 [Abstract] [Full Text]  
  • Wong, R. P. M., Davis, T. M. E. (2009). Statins as Potential Antimalarial Drugs: Low Relative Potency and Lack of Synergy with Conventional Antimalarial Drugs. Antimicrob. Agents Chemother. 53: 2212-2214 [Abstract] [Full Text]  
  • Haldar, K. (2008). Targeting the Host to Control an Infection Disorder. Arch Intern Med 168: 2067-2068 [Full Text]  
  • Botelho-Nevers, E., Espinosa, L., Raoult, D., Rolain, J.-M. (2008). Lovastatin, but not pravastatin, limits in vitro infection due to Coxiella burnetii. J Antimicrob Chemother 62: 845-847 [Full Text]  
  • Bhatnagar, S., Shinagawa, K., Castellino, F. J., Schorey, J. S. (2007). Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. Blood 110: 3234-3244 [Abstract] [Full Text]  
  • Pradines, B., Torrentino-Madamet, M., Fontaine, A., Henry, M., Baret, E., Mosnier, J., Briolant, S., Fusai, T., Rogier, C. (2007). Atorvastatin Is 10-Fold More Active In Vitro than Other Statins against Plasmodium falciparum. Antimicrob. Agents Chemother. 51: 2654-2655 [Full Text]  
  • Gupta, R., Plantinga, L. C., Fink, N. E., Melamed, M. L., Coresh, J., Fox, C. S., Levin, N. W., Powe, N. R. (2007). Statin Use and Hospitalization for Sepsis in Patients With Chronic Kidney Disease. JAMA 297: 1455-1464 [Abstract] [Full Text]  
  • Goluszko, P., Nowicki, B. (2005). Membrane Cholesterol: a Crucial Molecule Affecting Interactions of Microbial Pathogens with Mammalian Cells. Infect. Immun. 73: 7791-7796 [Full Text]  
  • Erkkila, L., Jauhiainen, M., Laitinen, K., Haasio, K., Tiirola, T., Saikku, P., Leinonen, M. (2005). Effect of Simvastatin, an Established Lipid-Lowering Drug, on Pulmonary Chlamydia pneumoniae Infection in Mice. Antimicrob. Agents Chemother. 49: 3959-3962 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»